The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma

Jiliang Shen a, #, Chiung-Kuei Huang b, #, Hong Yu a, Bo Shen a, Yaping Zhang c, Yueling Liang a, Zheyong Li a, Xu Feng a, Jie Zhao a, Lian Duan a, Xiujun Cai a, *

a Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
b Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA
c Department of Anesthesiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China

Received: April 18, 2016; Accepted: June 29, 2016

Abstract

Exosomes are small vesicles that were initially thought to be a mechanism for discarding unneeded membrane proteins from reticulocytes. Their mediation of intercellular communication appears to be associated with several biological functions. Current studies have shown that most mammalian cells undergo the process of exosome formation and utilize exosome-mediated cell communication. Exosomes contain various microRNAs, mRNAs and proteins. They have been reported to mediate multiple functions, such as antigen presentation, immune escape and tumour progression. This concise review highlights the findings regarding the roles of exosomes in liver diseases, particularly hepatitis B, hepatitis C, liver cirrhosis and hepatocellular carcinoma. However, further elucidation of the contributions of exosomes to intercellular information transmission is needed. The potential medical applications of exosomes in liver diseases seem practical and will depend on the ingenuity of future investigators and their insights into exosome-mediated biological processes.

Keywords: exosome ● HBV ● HCV ● liver cirrhosis ● hepatocellular carcinoma

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are two types of viruses that infect the liver and replicate in hepatocytes [1]. Approximately 2 billion people are infected with HBV, and nearly 170 million people are chronically infected with HCV worldwide [2, 3]. Some of them develop progressive chronic liver diseases (CLD), including hepatitis, fibrosis, cirrhosis and even hepatocellular carcinoma (HCC) [4]. Although there is a highly efficacious vaccine for HBV, many issues still exist, including vaccine cost, vaccine non-compliance, vaccine non-responsiveness and vaccine escape mutations [5]. Antiviral nucleoside analogues against HBV were developed to resolve these issues, but drug resistance remains a problem. Sofosbuvir, a nucleotide analogue of the HCV NS5B polymerase inhibitor of all HCV genotypes, is still in a phase 3 clinical study [6]. HBV and HCV remain concerns for humans.

Liver cirrhosis is the 14th most common cause of death worldwide and is an increasing cause of morbidity and mortality in developed countries [7]. HBV and HCV infection, alcohol abuse, and non-alcoholic liver diseases are the main causes of liver cirrhosis in developed countries. However, HBV infection is the most common cause of liver cirrhosis in sub-Saharan Africa and most parts of Asia [8]. Liver cirrhosis is a dynamic process, and it may eventually cause decompensation and end-stage disease requiring liver transplantation.

Hepatocellular carcinoma is the most common primary liver cancer. Approximately, 80% of HCC cases are associated with chronic HBV or HCV infection and liver cirrhosis [9]. HBV and HCV infections are considered major HCC risk factors worldwide. In addition, obesity-related type 2 diabetes mellitus, alcohol and tobacco are risk factors for HCC [10–12]. According to recent studies, more than 500,000 deaths are caused by HCC annually. Meanwhile, the incidence of HCC is increasing, making HCC an important public health burden [9, 13, 14].

© 2016 The Authors.
Exosomes in liver disease

Exosomes were first identified in the intracellular production of small vesicles containing specific plasma membrane proteins in maturing mammalian reticulocytes [15]. Before being released into the extracellular milieu, exosomes were identified intracellularly in multivesicular bodies (MVBs) [16–18]. They were secreted with a diameter of 40–100 nm and a density in sucrose gradients of 1.13–1.19 g/ml, were found to have an endocytic origin and were enriched with tetraspanin molecules [19–22]. Exosomes were initially considered a mechanism for discarding membrane proteins, such as transferrin receptors, in mature red blood cells [15]. Later, several studies revealed their role in intercellular communication without the need for direct cell–cell contact. Exosomes have the capacity to act as antigen-presenting vesicles and stimulate antitumoural immune responses [23]. Different types of viruses, such as human immunodeficiency virus, HBV and HCV, utilize exosomes to transfer signalling-compotent proteins and functional microRNAs to uninfected cells [24–29]. In addition, the literature increasingly indicates that exosomes may be secreted by tumour cells to promote tumour progression or suppress immune responses to tumours [30–33]. Similar to HBV and HCV, exosomes also play a role in liver cirrhosis and hepatocellular cancer. This review will mainly focus on the role of exosomes in liver diseases, including viral hepatitis, liver cirrhosis and hepatocellular carcinoma.

The role of exosomes in HBV

HBV is a member of the Hepadnaviridae family that exclusively infects hepatocytes [34]. Approximately 2 billion people are infected with HBV, and IFN-α has proven to be an effective treatment for chronic infection [35]. Li's study revealed that IFN-α-induced antiviral responses could be transmitted from liver non-parenchymal cells (LNPCs) to HBV-infected hepatocytes via exosomes and thus restore the antiviral state in hepatocytes. The antiviral response induced by IFN-α could be transmitted from LNPCs to HBV-infected hepatocytes via exosomes containing antiviral molecules. Exosome mediated and enhance the anti-HBV treatment effects of IFN-α [36].

Recent studies highlighted the importance of exosomes in cell-to-cell communication [37, 38], and some specific exosomes were detected as biomarkers for different liver diseases [39]. Marked and specific changes in exosome protein contents were also detected by comparing exosomes secreted by HBX-infected HuH7 cells with those secreted by a control group [40]. HCC-related proteins, such as VCP, were detected in the serum exosomes of HBV-infected patients. Detecting and understanding the changes associated with HBV-specific exosomes may provide a new perspective regarding the diagnosis of HBV or HBV-related HCC.

The role of exosomes in HCV

Exosomes mediate cell–cell communication via the transfer of proteins, mRNAs and microRNAs [41]. A previous study in HCV-infected patients revealed the presence of HCV viral RNA in exosomes [28]. Ramakrishnaiah's study [42] demonstrated an exosomal route of HCV transmission between hepatocytes. Further study indicated that infections involving HCV exosomes showed a higher level of HCV transmission to hepatocytes than the same multiplicity of infection (MOI) of free HCV particles [43]. Some studies have suggested that exosomal HCV RNA is transmitted as a complex consisting of Ago2, HSP90 and miR-122 and that this protein complex was proven to enhance HCV RNA stability and viral replication [43–46] (Fig. 1A) . HCV exosomes are a clever strategy that may be used by the virus to ensure effective replication and may explain HCV treatment resistance with interferon. These findings may also provide new drugs that target HCV RNA-related exosomes.

In addition to enhancing HCV transmission to hepatocytes, HCV-related exosomes are also involved in the innate immune response and immune escape [47, 48]. Plasmacytoid dendritic cells (pDCs) are a major IFN-α producing cell type and have the ability to rapidly secrete type 1 IFN after being activated [49]. The conventional mechanisms of pDC activation involve cell–cell contact and TLR7-dependent interactions with the intracellular HCV RNA of co-cultured infected cells [50–52]. HCV-infected cells could deliver their HCV RNA cargo to neighbouring pDCs by packaging viral RNA within exosomes [47] (Fig. 1B). However, the exosome transfer of HCV to pDCs occurred only when cells were in close proximity, which needs to be further studied. This new mechanism has broadened our understanding of the host–virus relationship and provided us with hints to better control HCV infections.

HCV-related exosomes are also involved in immune escape [48]. Gal-9, a ligand of Tim-3, could inhibit T cells, leading to immune dysfunction [53–55]. Significantly higher levels of gal-9 were detected in cultured monocytes from HCV patients than those from normal donors. The production of gal-9 was associated with T-cell inhibition in HCV infection. Further study indicated that close proximity and exosome release from HCV-infected cells promoted gal-9 secretion from monocytes (Fig. 1C). The adaptive immune inhibition associated with HCV infection that leads to viral persistence and targets specific HCV exosomes may represent a therapeutic target that enhances HCV treatment effects.

The role of exosomes in liver cirrhosis

Recently, several studies have reported on the function of exosomes in the process of liver fibrosis [56–59]. Connective tissue growth factor 2 (CCN2), which is overexpressed in fibrotic liver, could directly promote fibrogenesis in hepatic stellate cells (HSCs) [60]. The expression of CCN2 was also increased in activated HSCs compared with quiescent HSCs [61, 62]. MiR-214, which targets the CCN2 3′-UTR directly, regulated the expression of CCN2 and was transferred from HSCs to neighbouring cells by exosomes [56]. Normally, exosomal miR-214 has a limited impact on the fibrotic response in hepatic cells. However, miR-214 was decreased during chronic liver injury; therefore, CCN2 up-regulation may promote liver fibrosis (Fig. 2). MiR-214, a fibrosis-related miRNA, may have potential use as a non-invasive or minimally invasive biomarker of fibrosis progression. In addition, isolated exosomal miR-214 or mimicry may have a
therapeutic effect on liver fibrosis, but the mechanism underlying exosomal miR-214 down-regulation in chronic liver disease remains unclear. Further related studies will be needed to verify its efficacy.

In another study [57], exosomal Twist1, which drives miR-214 expression and facilitates CCN2 suppression in recipient cells, was reported to be suppressed during HSC activation. Suppression of exosomal Twist1 played a positive role in CCN2-dependent fibrogenesis. CCN2 could also be packaged into secreted exosomes by activated HSCs and transferred to other quiescent or activated HSCs [58]. The exchange of exosomal CCN2 may result in amplification of fibrogenic signalling in response to chronic liver injury. Targeting exosomal CCN2 may alleviate fibrosis progression.

During liver fibrosis, different exosomes are secreted to mediate fibrogenic signalling. Some exosomes may be specific to this process and can be used as biomarkers of liver fibrosis in the future. Some exosomes may be potential therapeutic targets. However, related studies are still rare, and further elucidation of the relationship between exosomes and liver fibrosis is needed.

The role of exosomes in hepatocellular carcinoma

Hepatocellular carcinoma is the fifth most common cancer in the world and the third most common cause of cancer-related death [13]. Genetic alterations in oncogenes and tumour suppressor genes have been extensively studied. However, the cellular microenvironment, including exosomal communications, remains less well understood. Previous studies have reported that exosomes are involved in HCC progression [63, 64]. Takayuki et al. [63] reported that HCC secreted
Exosomes containing various miRNAs. In terms of exosome-mediated intercellular signalling, these miRNAs mainly modulated TAK1 expression and signalling to promote development and progression of HCC. In addition, CD90+ HCC cells also promote angiogenesis in tumours via secreted lncRNA H19 exosome-mediated effects on endothelial cells [64] (Fig. 3A). Targeting these exosomes may better inhibit HCC progression.

Exosomes also play a role in mediating the effects of anti-tumour treatments. Using the exosomes secreted by adipose-derived mesenchymal stem cells (ADMSCs) to treat HCC in rats demonstrated significant suppression of HCC development. The anti-tumour response was mainly mediated by natural killer (NK) cells and could be enhanced by ADMSC-derived exosomes [65].

Heat shock proteins (HSPs) are a family of highly conserved proteins [66]. Anti-tumour immunity was enhanced after the host’s cellular immune system recognized tumour-derived exosomal HSPs [67]. After treatments with anti-cancer medicines, HCC cells delivered HSP-enriched exosomes to NK cells to enhance their anti-tumour bioactivity [68] (Fig. 3B). HSPs expressing tumour exosomes may represent a promising alternative approach to the treatment of HCC.

**Summary and future prospects**

More and more studies have revealed the roles of exosomes in liver diseases. The functions of exosomes mainly depend on the cells that receive exosome signals and contents [22, 69–71]. Current studies have presented the multiple functions of exosomes in liver diseases. In HBV treatment, exosomes transmit the antiviral response from LNPCs to HBV-infected cells [40]. HCV-infected cells secrete HCV RNA-exosomes, whose functions lead to infection (to hepatocytes) or initial immune activation (to pDCs) depending on where they are transmitted [46, 47]. Exosomes also play a role in the process of liver fibrosis by mediating communication between HSCs and hepatocytes. Decreased exosomal miR-214 is mostly detected at the initial stage of liver fibrosis and promotes the fibrotic process. However, the
mechanism underlying how these exosomes are down-regulated needs to be further studied in the future. HCC cells could secrete exosomes to deliver miRNA or lncRNA to surrounding cells, including other HCC cells or endothelial cells. Cell–cell communication mediated by these exosomes may promote tumour growth and angiogenesis [63, 64]. However, in anti-tumour treatment, HCC cells also secrete exosomes with enriched HSPs, which promote NK cell anti-tumour bioactivity [68].

In summary, one category of exosomes may be related to the development of liver diseases and may be valuable in diagnosis. Another category of exosomes plays a role in promoting hepatitis, cirrhosis and HCC. Targeting different types of exosomes may help clinicians to better control liver diseases. However, further studies will be needed to gain full knowledge of exosome formation and function to better utilize their capabilities.

Conflict of interest

All authors confirmed that there is no conflicts of interest.

References

1. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013; 13: 123–35.

2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337: 1733–45.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. 2013; 57: 1333–42.

4. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. *Semin Liver Dis*. 2005; 25: 212–25.

5. Huang Y, Tai AW, Tong S, et al. HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. *J Hepatol*. 2013; 58: 1068–73.

6. Hsu CS. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013; 369: 678.

7. Tsichatzi EA, Bosch J, Burroughs AK. Extrahepatic manifestations of chronic hepatitis C infection. *J Hepatol*. 2013; 369: 678.

8. Altekruse SF, McGlynn KA, Reichman ME. Environmental factors and carcinogenesis. *J Natl Cancer Inst*. 2007; 132: S72–S7.

9. Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci*. 2000; 113(Pt 19): 3985–74.

10. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood*. 1999; 94: 3791–9.

11. Johnstone RM, Adams M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987; 262: 9412–20.

12. Tsochatzis EA, Bosch J, Burroughs AK. Hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Liver Int*. 2013; 369: 678.

13. El-Serag HB, Rudolph KL. Environmental factors and carcinogenesis. *J Natl Cancer Inst*. 2007; 132: S72–S7.

14. Rehermann B, Nascimbeni M. Virus infection: new estimates of age-specific antibody to HCV seroprevalence. *J Hepatol*. 2011; 58: 393–608.

15. Schiel AE, Fijnheer R, et al. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015; 65: 87–108.

16. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol*. 2005; 5: 215–29.

17. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007; 132: 2557–76.

18. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol*. 2013; 58: 593–608.

19. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*. 2012; 142: 1264–73 e1.

20. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology*. 2004; 127: S72–8.

21. Adekunle SI, Ayodele LO, et al. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015; 65: 87–108.

22. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol*. 2005; 5: 215–29.

23. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007; 132: 2557–76.

24. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. *J Clin Oncol*. 2009; 27: 1485–91.

25. Pan BT, Johnstone RM. Fate of the transferin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell*. 1983; 33: 967–78.

26. Johnstone RM. Revisiting the road to the discovery of exosomes. *Blood Cells Mol Dis*. 2005; 34: 214–9.

27. Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci*. 2000; 113(Pt 19): 3985–74.

28. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood*. 1999; 94: 3791–9.

29. Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987; 262: 9412–20.

30. Tsochatzis EA, Bosch J, Burroughs AK. Hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Liver Int*. 2013; 369: 678.

31. Escola JM, Kleijmeer MJ, Stoerovogel W, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. *J Biol Chem*. 1998; 273: 20121–7.

32. Thery C, Bousso M, Veron P, et al. Pro- teomic analysis of dendritic cell-derived exosomes: a secreted sub cellular compartment distinct from apoptotic vesicles. *J Immunol*. 2001; 166: 7309–19.

33. Chaput N, Thery C. Exosomes: immune properties and potential clinical implementations. *Semin Immunopathol*. 2011; 33: 419–40.

34. Mack M, Kleinschmidt A, Brehm H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular transfer of microRNAs in living cells. *J Immunol*. 2011; 468: 5003–8.

35. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol*. 2005; 5: 215–29.

36. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007; 132: 2557–76.

37. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. *J Clin Oncol*. 2009; 27: 1485–91.

38. Pan BT, Johnstone RM. Fate of the transferin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell*. 1983; 33: 967–78.

39. Johnstone RM. Revisiting the road to the discovery of exosomes. *Blood Cells Mol Dis*. 2005; 34: 214–9.

40. Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci*. 2000; 113(Pt 19): 3985–74.

41. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood*. 1999; 94: 3791–9.

42. Thery C, Bousso M, Veron P, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. *J Immunol*. 2001; 166: 7309–19.

43. Chaput N, Thery C. Exosomes: immune properties and potential clinical implementations. *Semin Immunopathol*. 2011; 33: 419–40.

44. Mack M, Kleinschmidt A, Brehm H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular transfer of microRNAs in living cells. *J Immunol*. 2011; 468: 5003–8.
53. Rabinovich GA, Toscano MA. Hepatic exosomes establishes a productive infection. *J Hepatol*. 2014; 60: 674–5.

54. Dreux M, Garaigorta U, Boyd B, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe*. 2012; 12: 558–70.

55. Harwood NM, Golden-Mason L, Cheng L, et al. HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production. *J Leukoc Biol*. 2015; 99: 495–503.

56. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. *Nat Immunol*. 2004; 5: 1219–26.

57. Takahashi K, Asabe S, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. *Proc Natl Acad Sci USA*. 2010; 107: 7431–6.

58. Zhang S, Kodys K, Babcock GJ, et al. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. *Hepatology*. 2013; 58: 940–9.

59. Dental C, Florentin J, Asuar B, et al. Hepatitis C virus fails to activate NF-kappaB signaling in plasmacytoid dendritic cells. *J Virol*. 2012; 86: 1090–6.

60. Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. *Nat Rev Immunol*. 2009; 9: 338–52.

61. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. *Immunity*. 2012; 36: 322–35.

62. Ji XJ, Ma CJ, Wang JM, et al. HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Galectin-9 pathway. *Eur J Immunol*. 2013; 43: 458–67.

63. Chen L, Charrier A, Zhou Y, et al. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. *Hepatology*. 2014; 59: 1118–29.

64. Conigliaro A, Costa V, Lo Dico A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 IncRNA. *Mol Cancer*. 2015; 14: 155.

65. Ko SF, Yip HK, Chen YY, et al. Adipose-derived mesenchymal stem cell exosomes suppress hepatocellular carcinoma growth in a rat model: apparent diffusion coefficient, natural killer T-Cell responses, and histopathological features. *Stem Cells Int*. 2015; 2015: 853506.

66. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. *Science*. 1997; 278: 117–20.

67. Pockley AG. Heat shock proteins as regulators of the immune response. *Lancet*. 2003; 362: 469–76.

68. Lv LH, Wan YL, Lin Y, et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses *in vitro*. *J Biol Chem*. 2012; 287: 15874–85.

69. Thery C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *J Cell Biol*. 1999; 147: 599–610.

70. Wolters J, Lozier A, Raapos G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. *Nat Med*. 2001; 7: 297–303.

71. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med*. 1998; 4: 594–600.